AU2010312751B2 - Bridged artificial nucleoside and nucleotide - Google Patents

Bridged artificial nucleoside and nucleotide Download PDF

Info

Publication number
AU2010312751B2
AU2010312751B2 AU2010312751A AU2010312751A AU2010312751B2 AU 2010312751 B2 AU2010312751 B2 AU 2010312751B2 AU 2010312751 A AU2010312751 A AU 2010312751A AU 2010312751 A AU2010312751 A AU 2010312751A AU 2010312751 B2 AU2010312751 B2 AU 2010312751B2
Authority
AU
Australia
Prior art keywords
group
compound
carbon atoms
amino
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010312751A
Other languages
English (en)
Other versions
AU2010312751A1 (en
Inventor
Yoshiyuki Hari
Tetsuya Kodama
Masaru Nishida
Satoshi Obika
Aiko Yahara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Osaka NUC
Original Assignee
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC filed Critical Osaka University NUC
Publication of AU2010312751A1 publication Critical patent/AU2010312751A1/en
Application granted granted Critical
Publication of AU2010312751B2 publication Critical patent/AU2010312751B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010312751A 2009-10-29 2010-10-19 Bridged artificial nucleoside and nucleotide Active AU2010312751B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2009-248979 2009-10-29
JP2009248979 2009-10-29
JP2010-023209 2010-02-04
JP2010023209 2010-02-04
PCT/JP2010/068409 WO2011052436A1 (ja) 2009-10-29 2010-10-19 架橋型人工ヌクレオシドおよびヌクレオチド

Publications (2)

Publication Number Publication Date
AU2010312751A1 AU2010312751A1 (en) 2012-06-14
AU2010312751B2 true AU2010312751B2 (en) 2014-07-24

Family

ID=43921860

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010312751A Active AU2010312751B2 (en) 2009-10-29 2010-10-19 Bridged artificial nucleoside and nucleotide

Country Status (7)

Country Link
US (1) US8541562B2 (enExample)
EP (1) EP2495248B1 (enExample)
JP (2) JPWO2011052436A1 (enExample)
CN (1) CN102596983B (enExample)
AU (1) AU2010312751B2 (enExample)
CA (1) CA2778171C (enExample)
WO (1) WO2011052436A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5875006B2 (ja) 2010-08-31 2016-03-02 国立大学法人大阪大学 オリゴヌクレオチド、およびオリゴヌクレオチドを有効成分として含有する脂質異常症治療剤
JPWO2013089157A1 (ja) 2011-12-12 2015-04-27 独立行政法人国立循環器病研究センター オリゴヌクレオチド、およびオリゴヌクレオチドを有効成分として含有する高脂血症治療剤
EP2862868B1 (en) * 2012-06-18 2020-04-08 Daiichi Sankyo Company, Limited Intermediate for production of nucleoside analogue, and method for producing same
US10377789B2 (en) 2012-09-21 2019-08-13 Osaka University Oligonucleotide and artificial nucleoside having guanidine bridge
JP6270742B2 (ja) * 2013-01-10 2018-01-31 塩野義製薬株式会社 架橋型核酸誘導体の製造方法
JPWO2014112463A1 (ja) * 2013-01-15 2017-01-19 国立大学法人大阪大学 スルホンアミド構造を有するヌクレオシドおよびヌクレオチド
US9315535B2 (en) 2013-02-18 2016-04-19 Shionogi & Co., Ltd. Nucleoside and nucleotide having nitrogen-containing heterocycle structure
WO2015020194A1 (ja) * 2013-08-09 2015-02-12 国立大学法人大阪大学 Ａｃｓｌ１に対するアンチセンスオリゴヌクレオチド
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
JP6722586B2 (ja) * 2014-07-10 2020-07-15 賢二 中野 アンチセンス抗悪性腫瘍剤
CA2963288A1 (en) 2014-10-03 2016-04-07 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
JP2018140938A (ja) * 2015-07-24 2018-09-13 日産化学株式会社 人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド
TW201718618A (zh) * 2015-09-18 2017-06-01 田邊三菱製藥股份有限公司 架橋型核酸ＧｕＮＡ，其製造方法，及中間體化合物
AU2016334804B2 (en) 2015-10-09 2022-03-31 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
JP6569920B2 (ja) * 2016-01-07 2019-09-04 国立大学法人大阪大学 α−シヌクレイン発現抑制剤
EP3409779A4 (en) 2016-01-26 2019-07-03 Nissan Chemical Corporation Single-stranded oligonucleotide
JP6853537B2 (ja) 2016-02-17 2021-03-31 国立大学法人東京工業大学 人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
JP2020055750A (ja) * 2017-01-30 2020-04-09 賢二 中野 癌浸潤または転移阻害核酸薬
MX2019009305A (es) 2017-02-06 2019-09-19 Nissan Chemical Corp Oligonucleotido de cadena simple.
US11261440B2 (en) 2017-02-21 2022-03-01 Osaka University Antisense oligonucleic acid
WO2018155451A1 (ja) 2017-02-21 2018-08-30 国立大学法人大阪大学 核酸化合物およびオリゴヌクレオチド
EP3603648B1 (en) 2017-03-29 2025-09-17 Shionogi & Co., Ltd Complex of nucleic acid medicine and multibranched lipid
EP3604531A4 (en) 2017-03-31 2020-12-23 Aichi Medical University NUCLEIC ACID ANTISENS FOR INHIBITION OF CHONDROITIN SULPHATE BIOSYNTHESIS
US11273222B2 (en) 2017-05-26 2022-03-15 National Cerebral And Cardiovascular Center Antisense nucleic acid targeting PCSK9
WO2019009299A1 (ja) 2017-07-05 2019-01-10 国立大学法人大阪大学 α－シヌクレイン発現抑制するＥＮＡアンチセンスオリゴヌクレオチド
WO2019009298A1 (ja) * 2017-07-05 2019-01-10 国立大学法人大阪大学 α－シヌクレイン発現抑制剤
US11555188B2 (en) 2017-07-26 2023-01-17 Nissan Chemical Corporation Single-stranded oligonucleotide
LT3673080T (lt) 2017-08-25 2023-12-27 Stoke Therapeutics, Inc. Priešprasminiai oligomerai, skirti būklėms ir ligoms gydyti
TWI850773B (zh) 2017-08-31 2024-08-01 日商田邊三菱製藥股份有限公司 可溶性il-33受體的用途
EP3770256A4 (en) 2018-03-20 2021-12-22 Tokyo Institute of Technology OLIGONUCLEOTIDE ANTISENS WITH REDUCED TOXICITY
BR112020022512A2 (pt) 2018-05-04 2021-05-04 Stoke Therapeutics, Inc. métodos e composições para tratamento de doença de armazenamento de éster de colesteril
EP3831837A4 (en) 2018-07-31 2023-06-14 Osaka University OLIGONUCLEOTIDE THERAPEUTIC AGENT FOR SMALL CELL LUNG CANCER
WO2020203896A1 (ja) 2019-03-29 2020-10-08 シスメックス株式会社 新規人工核酸、その製造方法及び用途
CA3141874A1 (en) 2019-05-31 2020-12-03 Aligos Therapeutics, Inc. Modified gapmer oligonucleotides and methods of use
EP4005602A4 (en) 2019-07-30 2024-06-12 Shionogi & Co., Ltd NUCLEIC ACID AGENT TARGETED AGAINST MURF1
EP4023297A4 (en) 2019-08-27 2024-07-31 National University Corporation Tokai National Higher Education and Research System Nucleic acid medicine for targeting gastric cancer molecule
WO2021127406A1 (en) * 2019-12-19 2021-06-24 The Regents Of The University Of California Methods of producing target capture nucleic acids
WO2021132648A1 (ja) * 2019-12-27 2021-07-01 ルクサナバイオテク株式会社 Ｒｅｃｑｌの発現を阻害するアンチセンスオリゴヌクレオチド及びその用途
AR121490A1 (es) 2020-03-02 2022-06-08 Mitsubishi Tanabe Pharma Corp Prevención o tratamiento de aneurismas con substancia inhibidora de mir-33b
EP4130266A4 (en) 2020-03-26 2025-10-08 Nat Cerebral & Cardiovascular Ct ANTISENSE NUCLEIC ACID TARGETING APOC3
JP2023522961A (ja) 2020-04-21 2023-06-01 フラッグシップ パイオニアリング， インコーポレイテッド 二機能性分子およびその使用方法
EP4150092A4 (en) 2020-05-11 2024-11-06 Stoke Therapeutics, Inc. OPA1 ANTISENSE OLIGOMERS FOR THE TREATMENT OF DISEASES AND CONDITIONS
JP7725490B2 (ja) 2020-09-25 2025-08-19 株式会社理研ジェネシス 新規人工核酸、その製造方法及び用途
WO2022097727A1 (ja) 2020-11-06 2022-05-12 住友ファーマ株式会社 Ｒｐｓ２５遺伝子の発現及び／又は機能調節剤
JPWO2022181807A1 (enExample) 2021-02-25 2022-09-01
EP4331606A4 (en) 2021-04-30 2025-05-07 Kyoto University PREVENTION OR TREATMENT OF MYOPATHY USING A MIR-33B INHIBITOR
JPWO2022234855A1 (enExample) 2021-05-06 2022-11-10
CA3221758A1 (en) 2021-05-28 2022-12-01 Sumitomo Pharma Co., Ltd. Antisense nucleic acid
US20240390508A1 (en) 2021-08-21 2024-11-28 Takeda Pharmaceutical Company Limited Human transferrin receptor binding peptide-drug conjugate
EP4458836A4 (en) 2021-12-27 2025-05-21 Riken Genesis Co., Ltd. Novel artificial nucleic acid, method for producing same, and use of same
JPWO2023176920A1 (enExample) 2022-03-17 2023-09-21
WO2024101446A1 (ja) 2022-11-10 2024-05-16 ルクサナバイオテク株式会社 架橋部にグアニジノ構造を有する修飾ヌクレオシドおよびそれを用いたオリゴヌクレオチドの製造方法
WO2024257847A1 (ja) 2023-06-16 2024-12-19 住友ファーマ株式会社 Ｒｐｓ２５遺伝子の発現及び／又はその機能を調節するアンチセンスオリゴヌクレオチド
WO2025005265A1 (ja) * 2023-06-30 2025-01-02 日産化学株式会社 毒性が低減されたアンチセンスオリゴヌクレオチド
US20250368996A1 (en) 2024-05-14 2025-12-04 Aligos Therapeutics, Inc. Modified antisense oligonucleotides for treating hepatitis b virus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
YU73600A (sh) * 1998-05-26 2003-08-29 Icn Pharmaceuticals Inc. Novi nukleosidi koji imaju biciklične šećerne grupe
ES2431586T3 (es) 2002-02-13 2013-11-27 Takeshi Imanishi Análogos de nucleósidos y derivado de oligonucleótido que comprende un análogo de nucleótido del mismo
DK1661905T3 (da) 2003-08-28 2012-07-23 Takeshi Imanishi Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
JP5875006B2 (ja) * 2010-08-31 2016-03-02 国立大学法人大阪大学 オリゴヌクレオチド、およびオリゴヌクレオチドを有効成分として含有する脂質異常症治療剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NISHIDA, M. ET AL., Nucleic Acids Symposium Series, Vol. 51, pages 157-158 *

Also Published As

Publication number Publication date
CA2778171C (en) 2017-07-25
AU2010312751A1 (en) 2012-06-14
JP2014043462A (ja) 2014-03-13
JPWO2011052436A1 (ja) 2013-03-21
US8541562B2 (en) 2013-09-24
EP2495248A4 (en) 2013-10-16
JP5669073B2 (ja) 2015-02-12
CN102596983B (zh) 2016-06-15
CA2778171A1 (en) 2011-05-05
EP2495248A1 (en) 2012-09-05
US20120208991A1 (en) 2012-08-16
WO2011052436A1 (ja) 2011-05-05
EP2495248B1 (en) 2017-01-11
CN102596983A (zh) 2012-07-18

Similar Documents

Publication Publication Date Title
AU2010312751B2 (en) Bridged artificial nucleoside and nucleotide
US9611479B2 (en) Crosslinked nucleoside and nucleotide
JP6562517B2 (ja) 架橋型ヌクレオシドおよびヌクレオチド
JP5030998B2 (ja) ヌクレオシド類縁体およびそのヌクレオチド類縁体を含むオリゴヌクレオチド誘導体
JP7441523B2 (ja) ５’位修飾ヌクレオシドおよびそれを用いたヌクレオチド
JP2025066777A (ja) ヌクレオシド誘導体及びその利用
JP7438546B2 (ja) ５’位修飾ヌクレオシドおよびそれを用いたヌクレオチド
EP4108670A1 (en) Bridged nucleoside and nucleotide using same
JP7650412B2 (ja) ５′位修飾ヌクレオシドおよびそれを用いたヌクレオチド
JP2023110119A (ja) ５’位修飾ヌクレオシドおよびそれを用いたヌクレオチド
JP7709690B2 (ja) 架橋型ヌクレオシドおよびそれを用いたヌクレオチド
EP4617279A1 (en) Modified nucleoside having guanidino structure in bridged part and method for producing oligonucleotide using same
CN118946575A (zh) 5'位修饰核苷和使用其的核苷酸
WO2025095052A1 (ja) 炭素環式ヌクレオシド含有オリゴヌクレオチド
JPWO2003068794A1 (ja) 核酸糖部をｓ型に束縛したヌクレオシド類縁体およびそのヌクレオチド類縁体を含むオリゴヌクレオチド誘導体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)